Introduction
According to the European Association of Urology (EAU) guideline for BPH [1] , the phosphodiesterase type 5 inhibitor (PDE5i) tadalafil has been recommended for patients with BPH with LUTS as first-choice drugs, as well as a 1 -blockers. However, which of these two drug types should be recommended for which characteristics in patients with BPH has not been properly established. In daily clinical practice, there are sometimes patients who do not benefit from PDE5i treatment. Therefore, effective tools to predict the efficacy of PDE5i therapy for LUTS improvement in patients with BPH are needed.
Measurement of penile blood pressure (PBP) is a feasible and reproducible procedure. Some recent papers have reported that PBP reflects pelvic haemodynamics [2, 3] , which is thought to affect LUTS [4, 5] . Because PDE5i therapy that improves LUTS also increases pelvic blood flow [6] [7] [8] , PBP could be an effective tool for predicting the effects of PDE5i treatment. To elucidate whether PBP can identify patients who can benefit from tadalafil treatment, the correlations between PBP and changes in LUTS with tadalafil treatment were evaluated.
Patients and Methods

Study Design and Patients
We prospectively studied PDE5i-na€ ıve patients with BPH who had responded poorly to a 1 -blockers with IPSS qualityof-life (QoL) scores >3 and who were recruited at our hospital between September 2014 and December 2016. Patients were switched from a 1 -blockers to tadalafil 5 mg once daily. Patients were allowed to continue other medicines, such as 5a-reductase inhibitors, anticholinergic drugs and/or b 3 -adrenergic receptor agonists. Patients with prostate cancer, a history of TURP, atrial fibrillation, cognitive impairment, active UTI, and those who were ineligible for tadalafil were excluded. The patients' clinical characteristics before tadalafil treatment were evaluated and included: age; body mass index (BMI); smoking status (non-smoker, ex-smoker, current smoker); prostate volume, measured by transabdominal ultrasonography; diabetes mellitus; hyperlipidaemia; previous a 1 -blockers treatment; concomitant medication; maximum urinary flow rate (Q max ) on uroflowmetry; post-void residual urine volume (PVR); ankle-brachial index (ABI); brachial blood pressure; and scores of self-administered questionnaires, including the IPSS, IPSS-QoL, overactive bladder symptom score (OABSS), and the five-item version of the International Index of Erectile Function (IIEF-5).
PBP Measurement
PBP was measured using a cuff for a big toe, CUF-139 â (Fukuda Denshi Co. Ltd, Tokyo, Japan), around the penis of the patient in the supine position (Fig. 1) . The cuff pressure was measured by the vascular screening system Vasera VS-1500N â (Fukuda Denshi). PBP was measured before and at 4 and 12 weeks after tadalafil treatment. Information regarding adverse events (AEs) was collected at every visit.
Patients were divided into two groups using the median baseline PBP of 110 mmHg as the threshold: low-PBP group, patients with a PBP <110 mmHg; and high-PBP group, patients with a PBP ≥110 mmHg. Clinical characteristics before tadalafil treatment and changes in LUTS with tadalafil treatment were compared between the low-and high-PBP groups.
Correlation Between PBP and Changes in IPSS
Changes in LUTS with tadalafil treatment were evaluated by IPSS changes. The questionnaires have already been translated into Japanese, and their validity and reliability have been shown previously [9] . The IPSS was evaluated before and at 4 and 12 weeks after tadalafil treatment. Changes in the IPSS from baseline (i.e. DIPSS) were calculated and compared between the low-and high-PBP groups at 4 and 12 weeks.
Predictors of IPSS Improvements
Uni-and multivariate analyses were performed to identify parameters associated with IPSS improvement with tadalafil treatment. Several parameters that were considered probably to show relationships with IPSS improvement, such as age, BMI, smoking status, IPSS at baseline, IIEF-5, prostate volume, diabetes mellitus, hyperlipidaemia, kind of previous a 1 -blocker (tamsulosin, silodosin, naftopidil), concomitant medication, uroflowmetry parameters, ABI, brachial blood pressure and PBP, were examined.
Statistical Analysis
To compare patient characteristics between the low-and high-PBP groups, the Student's t-test was used for continuous data, and the chi-squared test was used for categorical data. Changes in the IPSS from baseline were compared at 4 and 12 weeks between the groups. Pearson's product-moment correlation coefficient and Student's t-test were used for univariate analyses, whilst multiple regression analysis was performed for multivariate analysis. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS â ) version 24 (SPSS Inc., IBM, Chicago, IL, USA). A P < 0.05 was considered statistically significant. Informed consent was obtained from all enrolled participants. All research protocols were approved by the Institutional Review Board Committee of the Shirakawa Kousei General Hospital.
Results
In all, 58 patients were registered. Within 4 weeks from the start of tadalafil treatment, three patients dropped out because of AEs, such as headache (Common Terminology Criteria for Adverse Events [CTCAE] [10] Grade 1), anterior chest pain (CTCAE Grade 1), and itching sensation (CTCAE Grade 2), and another four dropped out due to worse LUTS. Thus, 51 patients continued tadalafil for the entire 12 weeks. In all 51 patients, the PBP was stably measured without AEs, and no patient complained of discomfort or pain during the PBP examination. The response rates for these 51 patients before and at 4 and 12 weeks after the start of tadalafil treatment were all 100%. Table 1 shows the characteristics of the low-and high-PBP groups. The mean PBP was 96.5 mmHg in the low-PBP group and 121.8 mmHg in the high-PBP group. Amongst the other parameters investigated, there were significant differences in the IPSS at baseline, frequency of hyperlipidaemia and brachial blood pressure. IPSS at baseline was higher in the low-PBP group than in the high-PBP group. The frequency of hyperlipidaemia and brachial blood pressure was significantly higher in the high-PBP group than in the low-PBP group. Age, BMI, smoking status, prostate volume, IPSS-QoL, OABSS, IIEF-5, diabetes mellitus, history of oral drug intake, uroflowmetry parameters, and ABI did not show any significant differences between the groups. Figure 2 shows the IPSS changes with tadalafil treatment in the low-and high-PBP groups. The IPSS decreased in both the low-and high-PBP groups at 12 weeks. On the one hand, in the low-PBP group, the IPSS decreased immediately after the start of the treatment, and there was significant improvement from baseline at 4 (P = 0.029) and 12 (P = 0.001) weeks after the start of treatment. On the other hand, in the high-PBP group, the IPSS did not decrease during the first 4 weeks. The IPSS in the high-PBP group then decreased at 12 weeks, but the decrease was not significant. The improvements in the IPSS from baseline (DIPSS) at 4 and 12 weeks were significantly larger in the low-PBP group than in the high-PBP group (Fig. 3) .
Correlations Between Clinical Characteristics and PBP
Correlations Between PBP and IPSS Changes
Predictors of IPSS Improvement
On univariate analysis, PBP at baseline, brachial blood pressure and IPSS at baseline were significant predictors of IPSS improvement at 12 weeks of treatment. On multivariate analysis, the PBP at baseline, anticholinergic drug use, and IPSS at baseline, were significant predictors of a good IPSS Table 1 Patients' baseline characteristics.
Variable
Total patients (n = 51) Low-PBP group (n = 26) High-PBP group (n = 25) P (low-vs high-PBP group) Table 2 ).
Changes in PBP Before and After Tadalafil Treatment
On the one hand, the PBP in the high-PBP group decreased significantly after tadalafil treatment, from a mean (SD) of 121.8 (9.9) to 111.9 (14.8) mmHg. On the other hand, PBP in the low-PBP group showed a slight increase after tadalafil treatment, from a mean (SD) of 96.5 (8.7) to 99.5 (19.3) mmHg, but there was no significant difference (Fig. 4) .
Discussion
The results of the present study suggest that patients with BPH with a low PBP have greater benefits from tadalafil treatment than those with a high PBP. When patients were divided into two groups using the median baseline PBP of 110 mmHg, the IPSS in the low-PBP group decreased immediately after the start of tadalafil treatment. In the low-PBP group, there were significant improvements in the IPSS from baseline at 4 and 12 weeks after the start of treatment. The IPSS in the high-PBP group showed improvement at 12 weeks, but there was no significant difference. To the best of our knowledge, this is the first report to show that patients who could benefit from tadalafil treatment can be identified. This prospective study demonstrated that PBP, which is a feasible and reproducible procedure, could reliably identify candidates who could benefit most from tadalafil treatment.
It is considered that PBP reflects pelvic blood perfusion [2, 3] . Unno et al. and Inuzuka et al. [11, 12] investigated the relationship between PBP and pelvic blood perfusion in an abdominal aortic aneurysm operation model, and they showed that PBP was a sensitive reflection of pelvic haemodynamics. Schuler et al. [13] used PBP to assess the effect of femoro-femoral bypass for the treatment of lower extremity ischaemic symptoms on penile perfusion and erectile dysfunction in a 12-patient series. They reported that PBP increased significantly after surgery in four patients remedying their erectile dysfunction. They concluded that femoro-femoral bypass improved PBP by increasing pelvic perfusion, and a lower PBP was an indicator of chronic pelvic ischaemia. Chronic ischaemia of the pelvis, which is known to be induced by ageing, diabetes mellitus, and chronic heart disease, has been reported to be associated with deterioration of LUTS [5, 14, 15] . That the IPSS at baseline was worse in the low-PBP group than in the high-PBP group in the present study is consistent with the deterioration of LUTS in the presence of pelvic ischaemia.
PDE5i treatment, which increases blood supply and tissue oxygenation [8] , improved the IPSS in patients with BPH. In the present study, PDE5i treatment significantly improved the IPSS in the low-PBP group, whilst the improvement in the high-PBP group was not statistically significant. As one possible mechanism underlying the difference in the IPSS improvement between the two groups, we propose the following. In cases with low pelvic blood perfusion and/or pelvic ischaemia, as in the low-PBP group, tadalafil treatment may be able to elicit obvious improvements. However, pelvic blood perfusion in the high-PBP group was sufficient and thus unresponsive to tadalafil treatment. Pinggera et al. [16] reported that tadalafil did not result in increased prostate or bladder neck blood perfusion, because detection of blood perfusion changes was probably impossible due to already good baseline pelvic perfusion. A state of low PBP may be an advantageous situation for PDE5i treatment to achieve optimal efficacy for LUTS in patients with BPH.
In the present study, PBP itself was also changed after tadalafil treatment. On the one hand, PBP showed a slight increase in the low-PBP group. The increase probably indicated improvement in pelvic perfusion. On the other hand, PBP was significantly decreased in the high-PBP group at 12 weeks of tadalafil treatment. This decrease was considered to be due to the relaxing effects of tadalafil on the smooth muscle of vessels, not because of a decrease in pelvic perfusion.
The threshold value of PBP for beneficial effects from tadalafil treatment could not be defined in the present study because of the small numbers of patients. Validation in a larger population will be required to define the PBP threshold value in future.
In the present study, anticholinergic drug use was a predictor of IPSS improvement. The IPSS may be decreased in patients taking anticholinergic drugs because PDE5i have therapeutic potential in the treatment of overactive bladder (OAB) symptoms [17, 18] .
Patients on anticholinergic drugs would receive more benefit from tadalafil. However, in the present study, the b 3 -adrenergic receptor agonist mirabegron, which is also a drug for OAB, was not a predictor of IPSS improvement with tadalafil treatment. Recently, a new pathway in which badrenoceptor stimulation raises nitric oxide (NO) production in several organs has been identified [19] . Although the precise mechanisms have not been elucidated, the presence of sufficient NO, induced by mirabegron treatment, may not be advantageous for PDE5i to achieve optimal efficacy.
When interpreting the results of the present study, several limitations must be considered. First, patients with BPH who had responded poorly to a 1 -blockers were investigated. Thus, there may be selection bias. Second, both the non-randomised nature of the study and the small number of patients are major limitations. However, we think that the present data indicate that PBP could be a reliable tool to identify patients who could obtain beneficial effects from tadalafil treatment, as all LUTS data were collected prospectively using selfadministered questionnaires, and the response rates remained high throughout the study period. Even so, large, randomised, prospective studies will be needed to identify which patients with BPH-LUTS would be good candidates for tadalafil treatment.
In the present study, PBP at baseline was found to influence the treatment effects of tadalafil. These results may provide a clue as to why some patients fail to respond to tadalafil treatment. Treatment effects of other LUTS medications, such as a 1 -blockers, may also have potential to be gauged by PBP. In the future, more specifically designed, larger cohort studies are expected to identify those patients with BPH-LUTS who would benefit from which medical treatments. 
Conclusion
The present study demonstrated that PBP appears to be a reliable tool to identify patients with BPH-LUTS who could benefit from tadalafil treatment. PBP has a potential to help individualise medication for BPH-LUTS treatment. Patients with lower PBP (<110 mmHg) could be better responders to tadalafil.
